Development and Validation of a Health-related Quality of Life Instrument: Functional Assessment of Cancer Therapy - Immune Checkpoint Modulators, an Investigator Initiated Study (FACT-ICM).
This study aims to develop a health related quality of life (HRQOL) patient reported outcome
(PRO) for patients receiving immune checkpoint modulator (ICM) therapy. This instrument
could be used to in clinical trials to evaluate HRQOL for patients treated with novel ICMs
and ICM combinations that might ultimately influence decisions about regulatory approval, as
well as improved understanding of chronic treatment effects on patient well-being,
understanding reasons for treatment non-adherence, and developing strategies to improve
adherence and evaluating clinical outcomes.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society